Gyula Kovacs1,2, Lehel Peterfi3, Nelli Farkas4, Andras Javorhazy3, Csaba Pusztai3, Arpad Szanto3. 1. Medical Faculty, Ruprecht-Karls-University, Heidelberg, Germany. G.Kovacs@gmx.de. 2. Department of Urology, Medical School, University of Pecs, Munkacsy M. u. 2, Pécs, H-7621, Hungary. G.Kovacs@gmx.de. 3. Department of Urology, Medical School, University of Pecs, Munkacsy M. u. 2, Pécs, H-7621, Hungary. 4. Institute of Bioanalysis, Medical School, University of Pecs, Pecs, Hungary.
Abstract
BACKGROUND: The mortality of conventional renal cell carcinoma (RCC) correlates directly with the presence or postoperative development of metastases. The aim of this study was to identify new markers associated with the postoperative progression of conventional RCC. METHODS: Tissue microarrays (TMA) of conventional RCC from a cohort of 414 patients were analysed by immunohistochemistry for expression of the lipopolysaccharide binding protein (LBP), which was identified as a candidate biomarker through Affymetrix U133 Plus 2.0 array analysis. Univariate and multivariate Cox regression models were addressed to cancer-specific survival in association with age, sex, clinicopathological parameters and LBP expression. The survival time of the patients was estimated by Kaplan-Meier analyses, and comparisons of survival curves were made using the Log rank test. RESULTS: Univariate analysis revealed an association of patient survival with all clinicopathological parameters tested and LBP expression. In multivariate analysis only T classification, grade and LBP staining showed a significant association with postoperative cancer-specific survival (p < 0.001). LBP expression was found to be associated with a poor patient survival in Kaplan-Meier analyses. The estimated median survival time for patients with tumours showing LBP expression was 74 months, whereas the overall survival time was 142 months. CONCLUSION: LBP expression in conventional RCC defines a group of patients at a high risk of postoperative progression and may help to direct optimized active surveillance and timely adjuvant therapy.
BACKGROUND: The mortality of conventional renal cell carcinoma (RCC) correlates directly with the presence or postoperative development of metastases. The aim of this study was to identify new markers associated with the postoperative progression of conventional RCC. METHODS: Tissue microarrays (TMA) of conventional RCC from a cohort of 414 patients were analysed by immunohistochemistry for expression of the lipopolysaccharide binding protein (LBP), which was identified as a candidate biomarker through Affymetrix U133 Plus 2.0 array analysis. Univariate and multivariate Cox regression models were addressed to cancer-specific survival in association with age, sex, clinicopathological parameters and LBP expression. The survival time of the patients was estimated by Kaplan-Meier analyses, and comparisons of survival curves were made using the Log rank test. RESULTS: Univariate analysis revealed an association of patient survival with all clinicopathological parameters tested and LBP expression. In multivariate analysis only T classification, grade and LBP staining showed a significant association with postoperative cancer-specific survival (p < 0.001). LBP expression was found to be associated with a poor patient survival in Kaplan-Meier analyses. The estimated median survival time for patients with tumours showing LBP expression was 74 months, whereas the overall survival time was 142 months. CONCLUSION:LBP expression in conventional RCC defines a group of patients at a high risk of postoperative progression and may help to direct optimized active surveillance and timely adjuvant therapy.
Authors: E Faure; O Equils; P A Sieling; L Thomas; F X Zhang; C J Kirschning; N Polentarutti; M Muzio; M Arditi Journal: J Biol Chem Date: 2000-04-14 Impact factor: 5.157
Authors: G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar Journal: J Pathol Date: 1997-10 Impact factor: 7.996
Authors: S P K Jagdev; W Gregory; N S Vasudev; P Harnden; S Sim; D Thompson; J Cartledge; P J Selby; R E Banks Journal: Br J Cancer Date: 2010-11-09 Impact factor: 7.640
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Fabio Levi; Jacques Ferlay; Carlotta Galeone; Franca Lucchini; Eva Negri; Peter Boyle; Carlo La Vecchia Journal: BJU Int Date: 2008-01-30 Impact factor: 5.588